| Literature DB >> 31197363 |
Enrico Radaelli1, Sara F Santagostino2, Rani S Sellers3, Cory F Brayton4.
Abstract
In 1989 ILAR published a list and description of immunodeficient rodents used in research. Since then, advances in understanding of molecular mechanisms; recognition of genetic, epigenetic microbial, and other influences on immunity; and capabilities in manipulating genomes and microbiomes have increased options and opportunities for selecting mice and designing studies to answer important mechanistic and therapeutic questions. Despite numerous scientific breakthroughs that have benefitted from research in mice, there is debate about the relevance and predictive or translational value of research in mice. Reproducibility of results obtained from mice and other research models also is a well-publicized concern. This review summarizes resources to inform the selection and use of immune relevant mouse strains and stocks, aiming to improve the utility, validity, and reproducibility of research in mice. Immune sufficient genetic variations, immune relevant spontaneous mutations, immunodeficient and autoimmune phenotypes, and selected induced conditions are emphasized.Entities:
Keywords: biomedical research; experimental conditions; genetic background; genetic variation; immune system diseases; inbred strains; mice
Mesh:
Year: 2018 PMID: 31197363 PMCID: PMC7114723 DOI: 10.1093/ilar/ily026
Source DB: PubMed Journal: ILAR J ISSN: 1084-2020
Selected Immune Relevant Genetic Variations in Common Inbred Mouse Strains
| Gene symbol | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse strain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N/A |
| N/A | N/A | Ø | S | R | N/A | Ø | N/A | N/A | R | N/A | N | 2 |
|
|
| N/A |
| N/A | N/A | Ø | N/A | R | N/A | Ø | N/A | N/A | R | N/A | N | 1 |
|
|
| N | N | N/A | N/A | Ø | R | S | N/A | Ø | L29V | 2 | S | N | N | 2 |
|
|
| N/A | N/A | N/A | N/A | Ø | N/A | S | N/A | Ø | N/A | N/A | R | N/A | N | 1 |
|
|
| N | N | N/A | N/A | Ø | N/A | S | N/A | Ø | N/A | N/A | R | N/A |
| 1 |
| C3H/HeN |
| N/A | N | N/A | N/A | Ø | N/A | N/A | N/A | Ø | N/A | 1 | R | N/A | N | N/A |
|
|
| Ø | N | N | N | Ø | R | R | V | Ø | N | 1 | S | N | N | 1 |
|
| N/A | N/A | N | N/A | N | Ø | N/A | N/A | N/A | Ø | N/A | N/A | S | N/A |
| 1 |
|
|
| N/A | N | N/A | N/A | Ø | N/A | N/A | N/A | Ø | N/A | N/A | S | N/A | N | 1 |
|
|
| N/A |
| N/A | N/A | Ø | N/A | R | N/A | Ø | N/A | 2 | R | N/A | N | 2 |
|
| N/A | N/A |
| N/A | N/A | Ø | N/A | S | N/A | Ø | N/A | N/A | N/A | Ø | N | N/A |
|
| N/A | N/A | N |
| N/A | Ø | N/A | N/A | N/A | Ø | N/A | 2 | N/A | N/A | N | N/A |
|
| N/A | N/A |
|
| N/A | Ø | N/A | R | N/A | Ø | S | 2 | R | N/A | N | N/A |
|
|
| N/A | N | N/A | N/A | Ø | N/A | N/A | N/A | Ø | N/A | 2 | R | N/A | N | N/A |
|
| N/A | N/A | N | N/A | N/A | Ø | N/A | N/A | N/A | Ø | N/A | 2 | S | N/A | N | N/A |
|
| N/A | N/A | N | N/A | N/A | Ø | N/A | N/A | N/A | Ø | N/A | 2 | N/A | N/A | N | N/A |
|
|
| N/A | N |
| P | Ø | N/A | N/A | N/A | Ø | N/A | N/A | R | Ø | N | 1 |
|
|
| N/A |
| N/A | N/A | Ø | N/A | S | N/A | Ø | N/A | N/A | R | Ø | N | N/A |
|
|
| N | N | N/A | N/A | Ø | R | S | N/A | Ø | N/A | N/A | R | N | N | 1 |
(aryl hydrocarbon receptor) activates expression of phase I and II metabolizing enzymes (e.g., Cyp450) and is important in cellular growth and differentiation; b1, b2 and b3 alleles are considered metabolically responsive alleles not linked to autoimmunity whereas d alleles are metabolically nonresponsive and associated with autoimmune susceptibility.[37–40]
(cathepsin E) plays a role in antigen processing for MHC class II.[41]
(hemolytic complement) plays a role in innate immune responses; Hc mice are null for this allele.[42,43]
(interleukin 2) is a key immune signaling cytokine; Il2 allele has a hypoactive polymorphism in the Il2 gene.[44]
(interleukin 12b) polymorphisms (P) have been associated with autoimmune disorders in humans.[45–47]
(MX dynamin-like GTPase 1 & 2) play a role in viral resistance; in most inbred mouse strains, these are not expressed.[48,49]
(NLR family, apoptosis inhibitory protein 5) plays a key role in early innate immune responses mediated by the inflammasome; allelic polymorphism determines susceptibility to intracellular bacteria (Naip5 = sensitive, Naip5 = resistant).[50–52]
(nucleotide-binding oligomerization domain-like receptors aka NOD-like receptor proteins) has a key role in pathogen-associated molecular patterns detection.[53]
(NACHT, LRR and PYD domains-containing protein 12) has an important role in inflammasome and activation of caspase 1; it also controls neutrophil chemotaxis in response to bacterial invasion.[54–56]
(2’-5’ oligoA synthetase family 1b) plays a role in innate immunity to eliminate viral RNA; most inbred mouse strains carry the susceptibility allele that encodes for a nonfunctional protein.[57]
(signal-regulatory protein alpha); in BALB/c mice it has a single polymorphism in the IgV domain (L29V), which enhances binding to human CD47, decreasing macrophage phagocytosis; in NOD mice, the increased affinity for human CD47 is driven by a deletion of 2 amino acids in domain 1.[58,59]
[signaling lymphocytic activation molecule (SLAM) family] plays a role in self-tolerance;[60] haplotype 2 is associated with autoimmune susceptibility.[61–63]
[solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1] transporter that regulates iron homeostasis and impacts on the ability to control intracellular pathogens by phagocytes.[64]
(T cell receptor beta, variable 8) plays a role in auto-immune disease susceptibility; in some strains, this is not expressed and is associated with increased susceptibility to autoimmune disease.[65–67]
(Toll-like receptor 4) has a role in innate immune responses, in particular responses to LPS;[68–70] the mutant alleles Tlr4and Tlr4 are not functional.
Th-bias; mice have TH-1 and TH-2 biases in their immune responses.[71,72]
N/A, no data; N, wild type (normal); NOD, nonobese diabetic; Ø, not expressed nonfunctional or hypofunctional gene product; P, polymorphism; R, resistance polymorphism; S, sensitive polymorphism; V, variable.
A Few B6 Substrains and Genetic Variations
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
|
|
| Jackson | N | Ø | Ø | N | N | N |
|
| Charles River | N/A | N/A | Ø | N | N | N | |
|
| Hsd/Envigo | N/A | N/A | N | Ø | Ø | N | |
|
| Hsd/Envigo | N/A | N/A | N | N | N | N | |
|
| Taconic | N/A | N/A | N | N | N | N | |
|
| Janvier | N/A | N/A | N/A | N/A | N/A | N/A | |
|
|
| Jackson | N | N/A | N | N | N | Ø |
|
| Hsd/Envigo | Some Ø | N/A | N | N | N | Ø | |
|
| Janvier | N | N/A | N/A | N/A | N/A | N/A | |
|
| Charles River | N | N/A | N | N | N | Ø | |
|
| Taconic | N | N/A | N | N | N | Ø | |
|
| NCI | N/A | N | N/A | N/A | N/A | N/A | |
|
|
[ |
[ |
[ |
[ |
[ |
[ | ||
Adapted/updated from https://www.envigo.com/resources/data-sheets/envigo-68-c57bl6-enhanced-technical-data-sheet_screen.pdf
Dock2 = the protein encoded by this gene belongs to the CDM protein family. It is specifically expressed in hematopoietic cells and is predominantly expressed in peripheral blood leukocytes. The protein is involved in remodeling of the actin cytoskeleton required for lymphocyte migration in response to chemokine signaling. It activates members of the Rho family of GTPases, for example RAC1 and RAC2, by acting as a guanine nucleotide exchange factor (GEF) to exchange bound GDP for free GTP.
Nlrp12 = This gene encodes a member of the CATERPILLER family of cytoplasmic proteins. The encoded protein, which contains an N-terminal pyrin domain, a NACHT domain, a NACHT-associated domain, and a C-terminus leucine-rich repeat region, has an important role in inflammasome and activation of caspase 1, it also controls neutrophil chemotaxis in response to bacterial invasion.
Nnt = nicotinamide nucleotide transhydrogenase; this gene encodes an integral protein of the inner mitochondrial membrane. The enzyme couples hydride transfer between NAD(H) and NADP(+) to proton translocation across the inner mitochondrial membrane.
Snca = alpha synuclein; one in a family of structurally related proteins that are prominently expressed in the brain, particularly in areas associated with learning and adaption. The exact function of alpha synuclein is not yet known.
Mmrn1 = multimerin 1; multimerin 1 is a stored platelet and endothelial cell adhesive protein that shows significant conservation. In vitro, multimerin 1 supports platelet adhesion and it also binds to collagen and enhances von Willebrand factor-dependent platelet adhesion to collagen.
Crb1 = retinal degeneration 8; the rd-8 mutation is due to a single base pair mutation in the CRB1 gene. This gene when mutated in humans is linked to macular degeneration and other age-related vision loss. Mice with this mutation are nearly blind by the time they are 8 weeks of age.
N/A, no data; N, wild type (normal); Ø, not expressed, nonfunctional or hypofunctional gene product.
aJ mice distributed by Charles River in EU
Overview of Immunologically Relevant Mouse Models that Combine Multiple Spontaneous Mutations
|
|
|
|
|
|---|---|---|---|
|
| C3H/HeJ |
|
[ |
|
| MRL/MpJ |
|
[ |
|
| C57BL/6J |
|
[ |
|
| MRL/MpJ; C.B-17 |
|
[ |
|
| MRL/MpJ; C57BL/6J |
|
[ |
|
| C57BL/6J; N:NIH(S) |
|
[ |
|
| N:NIH(S) | Defective T ( |
[ |
|
| N:NIH(S); KSN | Defective T ( |
[ |
|
| N:NIH(S) | Combined athymia and asplenia; defective T cell maturation and function; reduced B cell number; hypogammaglobulinemia; increased incidence of spontaneous mammary tumors compared to single-mutant founder lines. |
[ |
|
| SB/Le |
|
[ |
|
| BXSB |
|
[ |
|
| C.B-17 | Defective T, B ( |
[ |
|
| SCID Hairless Outbred (Crl:SHO) | Impaired B and T cell development ( |
[ |
|
| 129/RI; BALB/c |
|
[ |
|
| BALB/cAJcl; C57BL/6J | Athymia combined with lack of secondary lymphoid organs including lymph nodes, splenic white pulp, Peyer’s patches and isolated lymphoid organs; severe immunodeficiency with impaired humoral and cell- mediated immune responses; preserved intestinal γδ-IEL subset; confirmation that thymus and secondary lymphoid organs are not an essential requirement for the development of γδ-IEL. |
[ |
IEL, intraepithelial lymphocytes; NK, natural killer.
Induced Immunodeficiencies (Intended Experimental Interventions)
|
|
|
|
|---|---|---|
|
| ||
| γ rays and X rays | Suppression of bone marrow resulting in marrow atrophy and pancytopenia. |
[ |
| High dose: decreased splenic and thymic weights; loss of cortical thymocytes; decreased splenic CD4+ and CD8+ T cells; decreased circulating CD3+ cells. | ||
| Chronic low dose: prolonged life span in mice homozygous for the lymphoproliferation spontaneous mutation ( | ||
| Other: acute radiation syndrome and death in | ||
| α and β particles | Release of DAMPs; activation of DCs; systemic and long-lasting T cell-mediated antitumor response in tumor-bearing mice; efficacy of α and β emitter-labeled monoclonal antibodies against fungal infections in mice. |
[ |
| Other: radiation nephropathy. | ||
| UVB | Immunosuppressed contact hypersensitivity ( |
[ |
| Narrowband (NB)-UVB: increased intestinal Tregs, and decreased severity of inflammatory lesions in mouse models of allogeneic GVHD. | ||
| UVA | High dose: increased IFNγ, IL12, and heme oxygenase; inhibited increment of IL10 from UVB exposure. |
[ |
| Medium dose: NO-mediated depletion of epidermal Langerhans cells; impaired development of skin memory CD8+ T cells in a mouse model of contact hypersensitivity. | ||
|
| ||
| Endogenous and exogenous glucocorticoids | Direct and receptor-mediated immunosuppression: attenuated DC activity; decreased DC number (apoptosis, tissue redistribution); enhanced inflammation; thymic atrophy (decreased DP thymocytes); dampened T cell activation (interference with TCR signaling); suppressed responses of TH1 and TH17 cells; reduced immunoglobulins. |
[ |
| Other: osteopenia, decrease in bone formation rate and mineral apposition rate in skeletally mature and young mice; osteoporosis in CD-1 mice (mouse model of glucocorticoid-induced osteoporosis); cleft palate in A/J mice. | ||
| Cyclophosphamide (CYP; Cytoxan) | Direct immunosuppression: depletion of CD8+ resident DCs in murine spleen and lymph nodes, with subsequent decrease in Treg suppressive function; neutropenia; depletion of suppressor or regulatory T cells in diabetic NOD mice. |
[ |
| Other: enhanced antitumor efficacy by promoting proliferation/activation of adoptively transferred B and T cells after CYP-induced lymphodepletion in mice; reduced diversity of the fecal microbiota; hemorrhagic cystitis in C57BL/6 and DBA/2 mice; chronic cystitis in DBA/2 (CYP model of bladder pain syndrome); short root lengths and early apical foramen closure during molar root development in ICR mice; suppressed osteoblastogenesis and osteoclastogenesis in C57BL/6 male mice. | ||
| 5 FU | Direct immunosuppression: depletion of MDSCs, and stimulation of TH17 cells, IL17 production by CD4+ T cells, and tumor growth; no altered levels of circulating B, T, and NK cells. |
[ |
| Tacrolimus (FK506) | Receptor-mediated immunosuppression: immunosuppressive effects on CD4+ T cells; marked tumor-promoting effect (topical tacrolimus) with decreased CD4/CD8 ratio; reduced inflammation in models of allergic rhinitis, conjunctivitis and arthritis. |
[ |
| Other: nephrotoxicity. | ||
| Cyclosporin A (CsA) | Receptor-mediated immunosuppression, reversible inhibition of T cell proliferation and proinflammatory immune reactions; blockage of all the changes resulting from intercellular signaling and cross-talk between DCs to T cells. |
[ |
| Rapamicin | Receptor-mediated immunosuppression:Inhibition of mTOR: suppressed T cell activation, proliferation, and development of FoxP3+ cells; suppression of DC maturation, B cell activation, neutrophil chemotaxis and uptake of antigen by APCs. |
[ |
| Other: increases lifespan. | ||
| Busulfan; Treosulfan | Direct immunosuppression:Busulfan: highly myelosuppressive, minimally immunosuppressive; diminished NK cell activity; late-stage (residual) bone marrow injury; stimulation of neuroinflammation through MCP-1. |
[ |
| Treosulfan: high persisting myeloablation in BALB/c mice; more effective depletion of splenic B and T cells. | ||
|
| ||
| Thymectomy | Thymectomy (post-natal day 2-5): autoimmune hemolytic anemia, thyroiditis, gastritis, oophoritis, orchitis, and prostatitis at puberty due to lack of Tregs. |
[ |
| Splenectomy | Systemic immune unresponsiveness; absence of tolerance after ocular injections of antigen in F4/80-deficient mice; retardation of tumor growth in melanoma-bearing mice. |
[ |
|
| ||
| Anti-thymocyte globulin (ATG) | Depletion of naïve T cells; less effective on memory T cells in NOD mice. |
[ |
| Prevention of autoimmune encephalomyelitis through expansion of myelin antigen-specific Foxp3+ Tregs in a murine EAE model. | ||
| β-1,3-Glucan | Increased IL2, TNFα, IL17, IFNγ, and lymphocytes in mice treated with aflatoxin B1. |
[ |
| CpG oligodeoxynucleotides | In murine models of infections: TH1 cytokine expression, activation of DCs, NK, and B cells. | |
| Combined therapy with monoclonal antibodies: increased NK cell activity. | ||
| Bacterially derived ADP-ribosylating enterotoxins | CT toxin produced by |
[ |
| LT enterotoxin from | ||
| Anti-lymphocyte serum (ALS) | Long-term abrogation of autoimmunity in overtly diabetic NOD mice. |
[ |
| Monoclonal antibody (mAb) therapy | Anti-mouse CD20 mAbs: depletion of mature B cells; reduction of CD4+ T cells, but maintainance of the interactions, functions, and migration of DCs and CD4+T cells; unaffected CD8+ T cell reactivity; absent release of inflammatory cytokines with effects on T cells. |
[ |
| Anti-mouse CD4 mAbs: depletion of CD4+ T cells; expansion of CD8+ T cells with an effector phenotype and of tumor-reactive CD8+ T cells; compromised anti-tumor immune memory. | ||
| Anti-mouse CD8 mAbs: depletion of CD8+ T cells; decreased infiltration of CD4+ cells, neutrophils, and macrophages; downregulation of IL1β, IL6, TNFα, CXCL1, CCL2 and up-regulation of IL4 in a mouse model of wound healing. |
APCs, antigen-presenting cells; CIA, collagen-induced arthritis; CT, Cholera toxin; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; DP, double positive; EAE, experimental autoimmune encephalitis; GVHD, graft-versus-host disease; LT, heat labile toxin; MCP-1, monocyte chemoattractant protein 1; MDSCs, myeloid-derived suppressor cells; NK, natural killer cell; NO, nitric oxide; Tregs, regulatory T cells.
Other Immunomodulators, Including Unintended Immune Consequences of Husbandry and Environmental Factors, Clinical and Experimental Interventions
|
|
|
|
|---|---|---|
|
| ||
| Housing conditions | ||
| Caging | Individual ventilated cages (compared to static microisolator caging): decreased bioburden and risk of intercage infection spread; increased cold stress; decreased circulating leukocytes; decreased intracage ammonia levels and correlated nasal pathology. |
[ |
| Bedding | Experimentally relevant parameters influenced by the type of bedding: higher intracage ammonia levels with reclaimed wood pulp bedding; corncob bedding associated with decreased efficiency of feed conversion in mice fed a high-fat diet; hepatotoxicity associated with vermiculite and unbleached pulp from pine and eucalyptus; hepatic and mammary carcinogenesis associated with aromatic red cedar bedding; altered estrogen signaling mainly due to BPA residues; corncob bedding associated with increased aggressivity and social stress in females; drastically lower endotoxin levels and bioburden associated with paper bedding. |
[ |
| Single or group housing and social stressors | Group housing: negative social events associated with lower lymphocyte proliferation; lower level of antigen-specific IgG; granulocytosis; lymphopenia, higher predisposition to tumor development and progression, huddling associated with amelioration of cold stress. |
[ |
| Individual housing: decreased antibody production; worsened allergic skin reaction; increased cold stress. | ||
| Environmental enrichment | Reduced stress levels; reduced oxidative stress; enhanced NK antitumor functions; enhanced macrophage chemotaxis and phagocytosis; improved capacity to clear systemic microbial infection; enhanced lymphocyte chemotaxis and proliferation; increased lifespan. |
[ |
| Temperature and humidity | Thermoneutral housing temperature (26°–34°C): reduced tumor formation, growth rate and metastasis due to increased CD8+ T cells; reduced myeloid-derived suppressor cells and Tregs. |
[ |
| Sub-thermoneutral housing temperature (20°–26°C): suppressed immune responses; increased therapeutic resistance of tumor and GVHD severity; suppressed myeloid cells function; alternative activation of macrophages. | ||
| Elevated humidity: increased bioburden; high ammonia levels due to expansion in urea-converting microflora. | ||
| Environmental noise and vibration | Altered tumor resistance; immunosuppression; reduced body weight; reduced fertility. |
[ |
| Inappropriate handling; untrained personnel | Increased risk of infection associated with inappropriate PPE and insufficient sterilization of equipment; pain, discomfort and stress associated with frequent/improper handling. |
[ |
| Altered light-dark cycle | Suppressed immune response; decreased splenic T cells; continuous illumination associated with decreased CD8+ and CD4+ cells in thymus and lymph nodes. |
[ |
| Dim lights | Elevated nighttime light exposure in male mice associated with worsened inflammation and weight gain under high-fat diet regimen. |
[ |
|
| ||
| Caloric restriction | Immune effects: reduced H2O2, TNF α, IL6, IL2, IL10, NO, IFNγ; decreased macrophage activation; impaired NK cell function; reduced IgA in small intestine and serum IgG. |
[ |
| Other effects: increased lifespan; reduced age-related morbidities. | ||
| Protein-energy malnutrition | Impaired proliferation CD8+ T cells; modulation of intestinal IgA responses to rotavirus; increased duodenal γδ IELs; increased production of jejunal proinflammatory cytokines in response to bacteria. |
[ |
| Prolonged fasting (48–120 h) | Stress response due to activation of hypothalamic-pituitary-adrenal axis; thymic atrophy (apoptosis of cortical DP thymocytes). |
[ |
| High-fat diet (in C57BL/6 mice) | Suppression of delayed hypersensitivity; altered intestinal microbiota with stimulation of mucosal immunity; altered systemic metabolomes; inflammation of adipose tissue with release of adipokines, cytokines, and chemokines, and propagation of a chronic inflammatory state (inflamobesity). |
[ |
|
| CYP-treated mice: reinstated lymphocyte proliferation and macrophage phagocytic activity; stimulation of IL2, IL12, TNFα, IFNγ, NK cell cytotoxicity; decreased splenic necrosis. |
[ |
| Polyunsaturated fatty acids supplementation | Dietary DHA and AA associated with improved allergen-induced dermatitis as consequence of increased FoxP3+ T cells, elevated IL10, and decreased TNFα. |
[ |
| Water acidification | Switch from normal tap water to acidified water associated with severe and long-lasting stress. |
[ |
|
| ||
| Zinc deficiency | Thymic atrophy (loss of DP thymocytes); accelerated lymphopenia with loss of antibody and cell-mediated responses; decreased number of pre-B cells, better survival for pro-T cells and mature DP and CD8+ T cells; increased myeloid lineage in bone marrow. |
[ |
| Vitamin A deficiency | Decreased ILC3 and antibacterial responses; compensatory expansion in IL-13-producing ILC2 and increased anti-helminth responses; intestine devoid of CD4+ and CD8+ T cells; lower salivary IgA levels and increased serum IgG response in mouse model of influenza; decreased mucosal antigen-specific IgA responses. |
[ |
| Vitamin D deficiency | VDR-deficient mice: increased mature DCs in skin draining lymph nodes; decreased Th1-cell responses and induction of IL10-producing Tregs. |
[ |
|
| ||
| Estrogenic endocrine-disruptors | Isoflavones (genistein): thymic atrophy; suppression of delayed hypersensitivity; decreased splenic NK cells; decreased IFNγ in response to bacterial infection. |
[ |
| Mycotoxins (aflatoxins, deoxynivalenol, zearalenone): elevated IgA and IgE; kidney mesangial IgA deposits; polyclonal activation of IgA secreting cells; IgA autoantibody. | ||
| BPA (cages, water bottles): lupus-like syndrome (C57BL/6 mice); allergic airway disease (BALB/c mice). | ||
| Halogenated aromatic hydrocarbons (PCDFs;PCDDs) | Contaminated food and bedding: inhibited innate and adaptive immune responses; atrophy of lymphoid organs; TCDD targets thymic lymphoblasts. |
[ |
| Metals (As, Cd, Pb, Hg, Se) | Complex immune-modulating effects (immunosuppression and immunostimulation). |
[ |
| As: decreased DCs in mediastinal lymph nodes of influenza A-infected C57BL/6 mice. | ||
|
| ||
| MHV | MHV-3-infected C57BL/6: impairment of pre-B cells maturation and B cells functions. |
[ |
| A59-infected BALB/c: transient lymphocyte apoptosis in the thymus. | ||
| MHV-JHM-infected BALB/cByJ: functionally altered CD4+ and CD8+ T cells, and APCs. | ||
| Sendai virus | Interference with macrophage and their phagocytic activity, NK cells, and T and B cell function; increased isograft rejection. |
[ |
| MNV | Lethal infection in mice deficient for STAT1 and IFN receptors; alteration of immune/inflammatory parameters in diverse mouse models including |
[ |
| MuHV-1 | Loss of splenic T and B cells; interference with key coordinating role of DCs; functional impairment of macrophages and loss of response to cytokines; altered responses to mitogens, antigens, increased allograft rejection, delayed type hypersensitivity responses, and clearance of other pathogens; formation of anti-cardiac autoantibodies. |
[ |
| MuHV-3 | Thymic necrosis (specific targeting of CD4+ T cells in newborn mice); autoimmune gastritis in BALB/c and A strain; autoimmune oophoritis and production of antibodies to thyroglobulin. |
[ |
| MPV | Suppressed proliferation (spleen, popliteal lymph node), increased proliferation (mesenteric lymph node) in ovalbumin-primed mice; altered alloreactive T cells and abnormal CD8+ T cell rejection of tumors and skin allografts (BALB/c); rejection of syngeneic grafts. |
[ |
| MVM | MVM: oncolytic, cytotoxic, replicative cancer inhibitor; deregulation of the Raf signaling cascade. |
[ |
| MVMi: depressed myelopoeisis in neonatal BALB/c; depletion of hemopoietic precursors, leukopenia, and compensatory erythropoiesis in adult and neonate SCID mice. | ||
| Murine retroviruses | Insertional mutagenesis (with reintegration of endogenous retroviruses or transposition of retroelements): immune relevant mutation such as |
[ |
| Endogenous retroviruses in pancreatic islets: contribution to immune-mediated insulitis NOD mice. | ||
| LP-BM5-infected C57BL/6 mice: lymphadenopathy, splenomegaly; hypergammaglobulinemia; T and B cell dysfunctions; late appearance of B cell lymphomas; opportunistic infections. | ||
| LCMV | LCMV disease: all pathological alterations following infection are immune-mediated; prototype for virus-induced T-lymphocyte-mediated immune injury and for immune complex disease; protection from LCMV-induced disease conferred through immunesuppression; noncanonical type I IFN signaling responsible for lethality in LCMV-infected |
[ |
| MHV-68 | Experimental infections of laboratory mice to study the pathogenesis of human lymphoproliferative disorders associated with EBV. |
[ |
| Bacteria | Mortality/morbidity (sepsis) in immune deficient mice: |
[ |
| Abscesses: | ||
| Skin disease/morbidity: | ||
|
| ||
| Fungi |
|
[ |
|
| ||
| Biosecurity in immunodeficient mice | High risk of |
[ |
| Biosecurity: contaminated biologicals | Rodent pathogens (latent infections): contaminated serum with mousepox. |
[ |
| Human pathogens: contaminated human cell lines (humanized mice and patient derived xenografts mice). | ||
|
| ||
| Modulation of the microbiome | SFB associated with the development of IL17 and IL22-producing CD4+ T cells (TH17 cells) in the intestinal lamina propria of germ-free mice. |
[ |
|
| ||
|
| ||
| Tamoxifen-inducible | Estrogen-dependent and -independent tamoxifen immunomodulatory effect; shift from a TH1- to a TH2-mediated immune response. |
[ |
| Tetracycline/doxycycline-inducible Tet-Off/Tet-On system | Doxycycline-dependent modulation of immune and inflammatory functions including allotransplant rejection, response to LPS, neutrophil chemotaxis; tetracycline/doxycycline-induced dysbiosis. |
[ |
| Nitrosamines, nitrates, nitrites (mutagens, carcinogens) | DMN: suppression of both humoral and cell-mediated immunity. |
[ |
| ENU: lymphoma (AKR/J, C58/J, C57BL/6J, NOD/LtJ); myeloid malignancies (SWR/J, DBA/2J); thymic lymphoma with/without K-ras mutations. | ||
| TMP-SMX | TMP-SMX alone: no effect on hematopoiesis or immune cell functions. |
[ |
| TMP-SMX synergized with zidovudine: anemia, thrombocytopenia, lymphopenia, and neutropenia, decreased splenic macrophages, suppressed AC-dependent T cell responses. | ||
| Ivermectin | Immunomodulation of T-helper cells; decreased recruitment of immune cells and cytokines in a model of asthma; unintended activation of tamoxifen-regulated Cre fusion protein in T cells. |
[ |
| Estrogens (for engraftment of estrogen-dependent tumors) | Increased splenic neutrophils (estrogen-treated C57BL/6 mice); enhanced IFNγ expression; thymic atrophy (DERKO mice); myelosuppression (decreased pluripotent hematopoietic stem cells). |
[ |
| Synthetic estrogens (DES): altered thymic T cell differentiation through interference with positive and negative selection processes in prenatally exposed mice; functionally defective NK cells and increased tumor susceptibility in neonatally exposed female mice. | ||
| Other: increased trabecular bone mineral density, fat reduction and increased uterine weight (DERKO mice); fibro-osseous lesions (bone marrow replacement by fibrovascular stroma (KK/HlJ and NZW/LacJ female mice). | ||
| Androgens (for engraftment of androgen-dependent tumors) | Androgen stimulation: thymic involution resulting from decreased colonization of bone-marrow-derived stem cells; loss of thymic epithelial cells; thymocyte apoptosis; inhibition of CD4+ T cell differentiation through upregulation of phosphate Ptpn1; erythroid hyperplasia. |
[ |
| Castration: enhanced CD8+ T cell vaccine response to prostate-specific antigens. | ||
| Streptozotocin | Early lymphopenia in both blood and spleen; relative increased Tregs in spleen, peripheral blood, and lymph nodes; delayed islet and skin allograft rejection. |
[ |
| NPs | Suppression of systemic humoral immunity (multi wall carbon nanotubes); inhibition of T cell-mediated immunity (iron oxide NPs, fuellerene 60); myelosuppression (Sb2O3, Co, ZnO, TiO2 NPs); allergic reactions (Ag NPs); anti-inflammatory activity and inhibition of cellular responses induced by IL1B (citrate-coated gold NPs). |
[ |
|
| ||
|
| Activation of STING antiviral response by endonuclease activity of Cre recombinase. |
[ |
| CRISPR-Cas9 | Adaptive immune response against Cas9. |
[ |
| Tetracycline/doxycycline-inducible Tet-Off/Tet-On system | Apoptotic response in activated lymphocytes resulting from DNA binding by tTA/rtTA. |
[ |
| Classical reporter molecules | Increase in the CTL response against transplanted eGFP-expressing leukemia cells in BALB/c mice; IFNγ response to the dominant CTL epitope of Luc, with consequent restricted growth and metastatic activity of the reporter-labelled tumor cells in a mouse model of mammary adenocarcinoma; antigen specific activation of T cells to the reporter gene β-galactosidase, with loss of transgene expression. |
[ |
AA, arachidonic acid; AC, accessory cell; BPA, Bisphenol A; CTL, cytotoxic T lymphocyte; CYP, cyclophospharmide; DCs, dendritic cells; DERKO, double ER knockout mice; DES, diethylstilbestrol; DP, double positive; DHA, docosahexaenoic acid; DMN, dimethylnitrosamine; EBV, Epstein-Barr virus; eGFP, enhanced green fluorescent protein; ENU, N-ethyl-N-nitrosourea; GVHD, graft-versus-host disease; IBD, inflammatory bowel disease; IELs, intra-epithelial lymphocytes; ILC3, type 3 innate lymphoid cells; ILC2, type 2 innate lymphoid cells; LCMV, lymphocytic choriomeningitis virus; Luc, luciferase; MHV, mouse hepatitis virus; MHV-68, murine gammaherpesvirus 68; MNV, murine norovirus; MNM, minute virus of mice; MPV, mouse parvovirus; MuHV-1, murid herpesvirus 1 (mouse cytomegalovirus); MuHV-3, murid herpesvirus 3 (mouse thymic virus); NKs, natural killer cells; NPs, nanoparticles; PPE, personal protective equipment; rtTA, reverse tetracycline-controlled transactivator protein; SFB, segmented filamentous bacteria; TCDD, 2,3,7,8-tetrachlorodibenzodioxin; TMP-SMZ, trimethoprim/sulfamethoxazole; Tregs, regulatory T cells; tTA, tetracycline-controlled transactivator protein; VDR, vitamin D receptor.